Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04273932 · ClinicalTrials.gov registry record · Phase 1
Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease.
A Phase 1 study, sponsored by State University of New York at Buffalo.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT04273932 is a Phase 1 study that has completed, run by State University of New York at Buffalo. The registered enrollment target is 19 participants.
The verdict
NCT04273932, a Phase 1 study, has completed, sponsored by State University of New York at Buffalo.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This study aims to determine if one of three low doses of lithium therapy for 6 months can engage one or more blood-based therapeutic targets implicated in Parkinson's disease (PD) pathophysiology. Results of this study will help to determine if lithium therapy is worthwhile to further investigate as a potential disease-modifying therapy in PD, the optimal dose to study and the optimal PD subgroup most likely to benefit from lithium therapy.
Interventions
- DRUG Lithium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2019-10-17 |
| Est. Completion | 2023-08-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04273932
The ClinicalTrials.gov registry entry for NCT04273932 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is State University of New York at Buffalo, which has 243 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lithium is the first listed.
NCT04273932 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04273932 about?
NCT04273932 is a clinical study titled "Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease.". This study aims to determine if one of three low doses of lithium therapy for 6 months can engage one or more blood-based therapeutic targets implicated in Parkinson's disease (PD) pathophysiology. Results of this study will help to determine if lithium therapy is worthwhile to further investigate a...
What is the current status of trial NCT04273932?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2019-10-17. Estimated completion is 2023-08-12.
What interventions are being tested in trial NCT04273932?
The interventions under investigation include: Lithium (DRUG).
Who is sponsoring clinical trial NCT04273932?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.